Rimonabant: The first therapeutically relevant cannabinoid antagonist

被引：78

作者：

Carai, MAM

Colombo, G

Gessa, GL

机构：

[1] Univ Cagliari, Bb Brodie Dept Neurosci, I-09126 Cagliari, Italy

[2] CNR, Inst Neurosci, I-09126 Cagliari, Italy

来源：

LIFE SCIENCES | 2005年 / 77卷 / 19期

关键词：

rimonabant (SR 141716); cannabinoid CB1 receptor; drug addiction; food intake; body weight;

D O I：

10.1016/j.lfs.2005.04.017

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

The present paper synthetically reviews the multiple experimental lines of evidence indicating the ability of the prototypic cannabinoid CB1, receptor antagonist, rimonabant (also known as SR 141716), to suppress the reinforcing/rewarding properties of different drugs of abuse, including cocaine, heroin, nicotine and alcohol, in laboratory rodents. This paper also reviews the data demonstrating that rimonabant reduces food intake and body weight in laboratory animals and humans. Taken together, the data reviewed here suggest that rimonabant may constitute a new and potentially effective medication for the treatment of drug addiction and obesity-related disorders. (c) 2005 Elsevier Inc. All rights reserved.

引用

收藏

页码：2339 / 2350

页数：12

相关论文

共 66 条

[1] Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors [J].

Arnone, M ;

Maruani, J ;

Chaperon, F ;

Thiebot, MH ;

Poncelet, M ;

Soubrie, P ;

LeFur, G .

PSYCHOPHARMACOLOGY, 1997, 132 (01) :104-106

[2]

BELL RL, 2004, SOC NEUR WASH DC PRO

[3] The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells [J].

Bensaid, M ;

Gary-Bobo, M ;

Esclangon, A ;

Maffrand, JP ;

Le Fur, G ;

Oury-Donat, F ;

Soubrié, P .

MOLECULAR PHARMACOLOGY, 2003, 63 (04) :908-914

[4] A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1 - Evidence for a new model of receptor/ligand interactions [J].

Bouaboula, M ;

Perrachon, S ;

Milligan, L ;

Canat, X ;

RinaldiCarmona, M ;

Portier, M ;

Barth, F ;

Calandra, B ;

Pecceu, F ;

Lupker, J ;

Maffrand, JP ;

LeFur, G ;

Casellas, P .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (35) :22330-22339

[5] Intracerebral self-administration of the cannabinoid receptor agonist CP 55,940 in the rat: interaction with the opioid system [J].

Braida, D ;

Pozzi, M ;

Parolaro, D ;

Sala, M .

EUROPEAN JOURNAL OF PHARMACOLOGY, 2001, 413 (2-3) :227-234

[6]

Caine SB, 1993, BEHAV NEUROSCIENCE P, P117

[7]

CARNI J, 2003, NEW ENGL J MED, V239, P975

[8]

Carr HA., 1989, NEUROPHARMACOLOGICAL, P264

[9] Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats [J].

Chaperon, F ;

Soubrié, P ;

Puech, AJ ;

Thiébot, MH .

PSYCHOPHARMACOLOGY, 1998, 135 (04) :324-332

[10] Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats [J].

Cheer, JF ;

Wassum, KM ;

Heien, MLAV ;

Phillips, PEM ;

Wightman, RM .

JOURNAL OF NEUROSCIENCE, 2004, 24 (18) :4393-4400

← 1 2 3 4 5 6 7 →